Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in stock prices, driven by recent government initiatives and the potential for significant market opportunities in healthcare and consumer sectors [1] Industry Summary - The National Medical Products Administration held a meeting on December 18 to promote the development of medical devices related to brain-computer interfaces, emphasizing the strategic importance of BCIs for future industries [1] - The meeting highlighted the need for safety and effectiveness as primary considerations, along with innovative regulatory methods and the establishment of a standard system [1] - There is a call for enhanced collaboration across various sectors, including industry, academia, and healthcare, to address key technological challenges and improve the supply chain [1] - Companies are urged to take responsibility for product reliability and competitiveness, aiming to expedite the clinical application of BCI devices for patient benefit [1] Company Summary - Stocks of companies involved in the BCI sector, such as Nanjing Panda (up 4.16% to HKD 4.51), MicroPort NeuroTech (up 4.24% to HKD 10.83), and BrainCo (up 2.58% to HKD 5.96), have seen significant increases [1] - Analysts from Guotai Junan point out that the BCI industry is poised for substantial growth due to technological breakthroughs, policy support, and capital investment, indicating a promising market outlook [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1]. Industry Summary - The brain-machine concept stocks opened high, with notable increases in share prices for companies such as Brainhole Aurora (06681) rising by 10.35% to HKD 6.29 and Nanjing Panda Electronics (00553) increasing by 1.63% to HKD 4.36 [1]. - A research team from the Chinese Academy of Sciences has successfully completed three invasive brain-machine interface clinical trials, achieving breakthroughs in real-life applications [1]. - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for independent mobility and object retrieval in real-life scenarios [1]. Company Summary - CITIC Securities believes that advancements in the midstream technology of the brain-machine interface industry are leading to breakthroughs in downstream applications, particularly in medical fields such as motor recovery, communication, and hearing restoration [1]. - The Chinese government and various regions have introduced multiple policies to accelerate the development of the industry, including a recent announcement from the National Healthcare Security Administration to separately list pricing for new brain-machine interface technologies [1]. - With technological innovations and policy incentives, domestic brain-machine interface companies are expected to gradually achieve commercial applications [1].

每经AI快讯，港股脑机概念股集体高开。截至发稿，脑洞极光(06681.HK)涨10.35%，报6.29港元；南京 熊猫电子股份(00553.HK)涨1.63%，报4.36港元。 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-computer concept stocks opened high, with notable increases such as Brainhole Aurora (06681) rising by 10.35% to HKD 6.29 and Nanjing Panda Electronics (600775) increasing by 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BCI clinical trials in collaboration with hospitals and enterprises, achieving breakthroughs in real-life applications [1] Clinical Trial Highlights - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for autonomous movement and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the midstream of the BCI industry are leading to breakthroughs in downstream applications, with significant milestones in medical fields such as motor recovery, communication, and hearing restoration [1] - National and regional policies are being introduced to accelerate industry development, including a recent announcement from the National Healthcare Security Administration to establish a separate pricing item for new BCI technologies, paving the way for clinical application service charges [1] - With technological innovations and policy support, domestic BCI companies are expected to gradually achieve commercialization [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-machine concept stocks opened high, with notable increases in share prices: Brainhole Aurora (06681) up 10.35% to HKD 6.29 and Nanjing Panda Electronics (00553) up 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BMI clinical trials, achieving breakthroughs in real-life applications [1] Clinical Trial Achievements - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for independent mobility and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the upstream BMI industry are leading to breakthroughs in downstream applications, particularly in rehabilitation, communication, and hearing restoration [1] - The Chinese government and various regions are implementing policies to accelerate the industry's development, including the National Healthcare Security Administration's recent decision to separately list pricing for new BMI technologies [1] - With technological innovations and policy support, domestic BMI companies are expected to gradually achieve commercial applications [1]

Group 1 - The core point of the article is that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 396 million into China International Capital Corporation Hong Kong Securities, representing 5.54% of the total [1] - The company announced that it, along with its Hong Kong subsidiary, will subscribe to financial products totaling USD 30 million, with investment scope excluding equity securities, on specific dates in March and April 2025 [1] - As of the announcement date, the financial products subscribed by the company and its Hong Kong subsidiary have been redeemed, and the group has no outstanding principal amount in these financial products [1]

Group 1 - The core point of the article is that Brainstorm Cell Therapeutics Inc. (脑动极光-B) has deposited shares worth HKD 396 million into China International Capital Corporation Hong Kong Securities, representing 5.54% of the total [1] - The company announced that it, along with its Hong Kong subsidiary, will subscribe to financial products totaling USD 30 million, with investment scope excluding equity securities, on specific dates in March and April 2025 [1] - As of the announcement date, the company and its Hong Kong subsidiary have redeemed the subscribed financial products, and the total principal amount of unrecovered financial products for the group is zero [1]

脑动极光-B(06681)发布公告，公司连同香港附属公司分别于2025年3月31日、2025年4月2日及2025年4 月3日认购本金总额为3000万美元的理财产品(其投资范围不包括股本证券)。于本公告日期，公司及香 港附属公司认购的理财产品已赎回，集团尚未赎回的理财产品本金总额为零。 ...

格隆汇12月15日丨脑动极光-B(06681.HK)宣布，公司连同香港附属公司分别于2025年3月31日、2025年4 月2日及2025年4月3日认购本金总额为3000万美元的理财产品(其投资范围不包括股本证券)。于本公告 日期，公司及香港附属公司认购的理财产品已赎回，集团尚未赎回的理财产品本金总额为零。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 上市規則的涵義 由於理財產品於12個月期間內完成向浦銀國際投資管理認購，因此，就根據上 市規則第14.22條計算有關百分比率而言，各認購事項相應本金額已按猶如與浦 銀國際投資管理進行一項交易般予以合計。鑒於在最後認購日期認購事項的最 高適用百分比率超過25%但低於100%，因此，就上市規則而言，認購事項技術 上構成本公司的主要交易而須遵守申報、公告、通函及股東批准規定。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 主要交易 認購及贖回理財產品 董事會宣佈，本公司連同香港附屬公司分別於2025年3月31日、2025年4月2日 及2025年4月3日認購本金總額為30百萬美元的理財產品（其投資範圍不包括股 本證券）。於本公告日期，本公司及香港附屬公司認購的理財產品已贖回，本集 團尚未贖回的理財 ...